Login
Not a registered user? REGISTER

Nurse Practitioner Healthcare Foundation

Continuing Education Program

Pain Managment and Opioids: Balancing Risks and Benefits 

Presented by:  Alan P. Agins, Ph.D.  &  Jody Agins, MSN, RNP, FNP/GNP-BC

A continuing education program for nurse practitioners, physicians, physician assistants, certified nurse midwives and RNs approved for 3.0 ANCC contact hours, 3.0 ACCME Category 1 credits, and 3 pharmacology hours

Course Objectives:

  • Accurately assess patients with pain for consideration of an opioid trial
  • Establish realistic goals for pain management and restoration of function
  • Initiate opioid treatment (IR and ER/LA) safely and judiciously, maximizing efficacy while minimizing risks
  • Monitor and re-evaluate treatment continuously; discontinue safely when appropriate
  • Counsel patients and caregivers about use, misuse, abuse, diversion, and overdose
  • Educate patients about safe storage and disposal of opioids
  • Demonstrate working knowledge and ability to access general and specific information about opioids, especially those used in your practice

Release Date: November 1, 2017

Expiration Date:   October 31, 2020

Accreditation Statements

The Nurse Practitioner Healthcare Foundation is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Upon completion, NPs and RNs will be awarded 3 contact and pharmacology hours.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Interstate Postgraduate Medical Association (IPMA) and the Nurse Practitioner Healthcare Foundation.

IPMA is accredited by the ACCME to provide continuing medical education for physicians. IPMA certifies that the person listed above has participated in this enduring activity and is awarded 3 AMA PRA Category 1 Credit(s) TM.

The AAPA and ACNM accept educational activities provided by organizations accredited by ACCME.  PAs and CNMs may report 3 hours of AMA PRA Category 1 credit.™

This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. 

CE Requirements
Requirements for successful completion of this CNE activity include downloading the handout (after registering), viewing all video segments, answering the assessment  questions embedded within the program and completing an online program evaluation. There is no partial credit.

Faculty / Planner Disclosures

  • Alan P. Agins, Ph.D.  has no conflicts of interest to report.
  • Jody Agins, MSN, RNP, FNP/GNP-BC has no conflicts of interest to report.
  • Pam Jenkins, MS, NP (Program Director & Lead Nurse Planner for NPHF) has no conflicts of interest to report.

Disclaimer

The information presented in this program is solely for educational purposes and should not be construed as specific instructions for the diagnosis or treatment of patients. Utilization of any information, derived from this program, in patient care remains strictly the professional responsibility of the health care provider. The health care provider is further advised to: (1) ascertain current FDA status of each drug and (2) consult current drug information guides, manufacturer product information or package inserts regarding the proper use, dosages, dosing schedules, contraindications, warnings and other pertinent prescribing and safety information. The Faculty (Alan Agins and Jody Agins) disclaim any liability, loss, injury or damage incurred as a consequence, directly or indirectly, from the use and application of any of the contents of this program. During the "Program" there may be occasional mention of proprietary or brand-name drugs. The mention or appearance of a specific proprietary product name should not be construed by the viewer that the Faculty, NPHF or CO*RE endorse or have specific bias toward that product or its manufacturer. Similarly, the absence of mention of a specific brand name should not imply that the product is deemed inferior to others in its class